Clinical trial
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary…
NCT00458315 · Rigshospitalet, Denmark, Other · Withdrawn
Key facts
| NCT number | NCT00458315 |
|---|---|
| Title | Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor |
| Official title | Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unknown Primary Tumors |
| Intervention type | Drug |
| Interventions | Cisplatin, Paclitaxel, Gemcitabine, Avastin (Bevacizumab) |
| Enrollment | 0 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2012 |
| First posted | Apr 10, 2007 |
| Last update posted | May 8, 2015 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: